发布求助
文献互助 智能选刊 最新文献

Pharmacogenomics最新文献

筛选
英文 中文
Correlation of ACE insertion/deletion gene polymorphism with captopril effectiveness in Indonesian hypertensive patients. 印度尼西亚高血压患者 ACE 插入/缺失基因多态性与卡托普利有效性的相关性。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/14622416.2024.2375190
Dewa A S Handani, Adam Hermawan, Zullies Ikawati
{"title":"Correlation of <i>ACE</i> insertion/deletion gene polymorphism with captopril effectiveness in Indonesian hypertensive patients.","authors":"Dewa A S Handani, Adam Hermawan, Zullies Ikawati","doi":"10.1080/14622416.2024.2375190","DOIUrl":"10.1080/14622416.2024.2375190","url":null,"abstract":"<p><p><b>Background:</b> Hypertension is a prevalent health concern in Indonesia, with a high percentage of patients unresponsive to ACE inhibitor treatment. <b>Methods:</b> This multicenter case-control study investigated the correlation between ACE I/D and captopril effectiveness in Indonesian hypertensive patients. Hypertensive patients were divided into control (n = 69) and case (n = 73) groups. <i>ACE I/D</i> was identified using PCR and electrophoresis.<b>Results:</b> No significant differences in genotype frequencies or allele distribution were observed. The difference of blood pressure reduction among the three genotypes also lacked statistical significance.<b>Conclusion: </b> <i>ACE I/D</i> is not significantly associated with blood pressure reduction following captopril therapy in Indonesian hypertensive patients. These results underscore the limited predictive utility of <i>ACE I/D</i> in managing hypertension with captopril.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788845","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis. IL-6和IL-10基因型对肾移植受者他克莫司剂量需求的影响：蒙特卡罗分析。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-07-29 DOI: 10.1080/14622416.2024.2379227
Nikola Stefanović, Katarina Danković, Tatjana Cvetković, Stevan Vujić, Ivan Pavlović, Tatjana Jevtović-Stoimenov, Branka Mitić, Radmila Veličković-Radovanović
{"title":"Impact of IL-6 and IL-10 genotypes on tacrolimus dose requirements in kidney transplant recipients: Monte Carlo analysis.","authors":"Nikola Stefanović, Katarina Danković, Tatjana Cvetković, Stevan Vujić, Ivan Pavlović, Tatjana Jevtović-Stoimenov, Branka Mitić, Radmila Veličković-Radovanović","doi":"10.1080/14622416.2024.2379227","DOIUrl":"10.1080/14622416.2024.2379227","url":null,"abstract":"<p><p><b>Introduction:</b> IL-6 and IL-10 may affect the activity of cytochrome P450 (CYP) 3A enzymes involved in tacrolimus (Tac) metabolism. Moreover, the effect of IL-6 and IL-10 on Tac pharmacokinetics may differ with respect to the genetic variations in their genes.<b>Aim:</b> To examine the influence of IL-6 and IL-10 gene polymorphisms on Tac dose requirements and exposure over a 5-year period following kidney transplantation. Univariate and standard multivariate linear regression and Monte Carlo analysis were performed to investigate potential covariates influencing Tac dose-adjusted trough concentration (C<sub>0</sub>/D) in various post-transplantation periods.<b>Materials & methods:</b> IL-6 (-174G > C), IL-10 (-1082G > A, -819C > T and -592C > A) genotype, Tac daily dose, C<sub>0</sub>, C<sub>0</sub>/D and intrapatient variability data were collected from 113 patients.<b>Results:</b> Multivariate regression analysis and accompanied Monte Carlo simulation underscore the importance of considering IL-6 -174G > C and IL-10 -1082G > A gene polymorphisms, alongside Tac metabolic phenotype and post-transplantation period, when tailoring Tac dosage regimen.<b>Conclusion:</b> This study provides valuable insights regarding the individualized adjustment of Tac treatment in various post-transplantation periods.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404698/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141788846","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Relevance of NAT2 genotype and clinical factors to risk for antituberculosis drug-induced liver injury. NAT2 基因型和临床因素与抗结核药物诱发肝损伤风险的相关性。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2023-12-22 DOI: 10.2217/pgs-2023-0148
Fang Cheng, Chao-Chao Qiu, Xian-Gao Jiang, Te Wu, Qiang Zhang, Xin Chen, Shi-Lin Zheng, Sai-Duo Liu, Xin-Chun Ye, Ji-Chan Shi
{"title":"Relevance of <i>NAT2</i> genotype and clinical factors to risk for antituberculosis drug-induced liver injury.","authors":"Fang Cheng, Chao-Chao Qiu, Xian-Gao Jiang, Te Wu, Qiang Zhang, Xin Chen, Shi-Lin Zheng, Sai-Duo Liu, Xin-Chun Ye, Ji-Chan Shi","doi":"10.2217/pgs-2023-0148","DOIUrl":"10.2217/pgs-2023-0148","url":null,"abstract":"<p><p>The study analyzes the risk factors associated with antituberculosis drug-induced liver injury (ATB-DILI), and the relationship between ATB-DILI and <i>NAT2</i> gene polymorphisms. Out of the 324 included patients, 57 (17.59%) developed ATB-DILI. Age, history of liver disease, alcohol consumption and timing of antituberculosis (ATB) treatment were independent risk factors for ATB-DILI in the patients with tuberculosis (TB; p < 0.05). There was a significant difference in the distribution of <i>NAT2</i> metabolic phenotypes between the study group and the control group (p < 0.05). The ATB drug treatment for pulmonary TB can cause a high incidence of ATB-DILI. Age, history of liver disease, alcohol consumption and timing of ATB treatment are independent risk factors for ATB-DILI in patients with TB.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138830882","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on HLA-B*15:02 allele associated with adverse drug reactions. 与药物不良反应相关的 HLA-B*15:02 等位基因的最新进展。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-02-02 DOI: 10.2217/pgs-2023-0173
Xueting Zhu, Guanghua Luo, Lu Zheng
{"title":"Update on <i>HLA-B*15:02</i> allele associated with adverse drug reactions.","authors":"Xueting Zhu, Guanghua Luo, Lu Zheng","doi":"10.2217/pgs-2023-0173","DOIUrl":"10.2217/pgs-2023-0173","url":null,"abstract":"<p><p>HLA alleles, part of the major histocompatibility complex, are strongly associated with adverse drug reactions (ADRs). This review focuses on <i>HLA-B*15:02</i> and explores its association with ADRs in various ethnic populations and with different drugs, aiming to provide insights into the safe clinical use of drugs and minimize the occurrence of ADRs. Furthermore, the review explores the potential mechanisms by which <i>HLA-B*15:02</i> may be associated with ADRs, aiming to gain new insights into drug modification and identification of haptens. In addition, it analyzes the frequency of the <i>HLA-B*15:02</i>, genotyping methods, cost-effectiveness and treatment measures for adverse reactions, thereby providing a theoretical basis for formulating clinical treatment plans.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139672403","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Potential association of SULT2A1 and ABCG2 variant alleles with increased risk for palbociclib toxicity. SULT2A1和ABCG2变异等位基因与帕博西尼毒性风险增加的潜在关联。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-08-02 DOI: 10.1080/14622416.2024.2380240
Chong Wang, Mary Hwang, Brandon Paulson, Doreen Mhandire, Sadat Ozair, Tracey L O'Connor, Shipra Gandhi, Kristopher M Attwood, Daniel L Hertz, Andrew Kl Goey
{"title":"Potential association of <i>SULT2A1</i> and <i>ABCG2</i> variant alleles with increased risk for palbociclib toxicity.","authors":"Chong Wang, Mary Hwang, Brandon Paulson, Doreen Mhandire, Sadat Ozair, Tracey L O'Connor, Shipra Gandhi, Kristopher M Attwood, Daniel L Hertz, Andrew Kl Goey","doi":"10.1080/14622416.2024.2380240","DOIUrl":"10.1080/14622416.2024.2380240","url":null,"abstract":"<p><p><b>Aim:</b> This study evaluated associations between <i>CYP3A4*22</i> and variants in other pharmacogenes (<i>CYP3A5</i>, <i>SULT2A1</i>, <i>ABCB1</i>, <i>ABCG2</i>, <i>ERCC1</i>) and the risk for palbociclib-associated toxicities.<b>Materials & methods:</b> Two hundred cancer patients who received standard-of-care palbociclib were genotyped and associations with toxicity were evaluated retrospectively.<b>Results:</b> No significant associations were found for <i>CYP3A4*22</i>, <i>CYP3A5*3</i>, <i>ABCB1</i>_rs1045642, <i>ABCG2</i>_rs2231142, <i>ERCC1</i>_rs3212986 and <i>ERCC1</i>_rs11615. Homozygous variant carriers of <i>SULT2A1</i>_rs182420 had higher incidence of dose modifications due to palbociclib toxicity (odds ratio [OR]: 4.334, 95% CI: 1.057-17.767, <i>p</i> = 0.042). <i>ABCG2_rs2231137</i> variant carriers had borderline higher incidence of grade 3-4 neutropenia (OR: 4.14, 95% CI: 0.99-17.37, <i>p</i> = 0.052).<b>Conclusion:</b> Once validated, <i>SULT2A1</i> and <i>ABCG2</i> variants may be useful to individualize palbociclib dosing to minimize toxicities and improve treatment outcomes.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141875602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evaluation of pharmacogenetic automated clinical decision support for clopidogrel. 评估氯吡格雷的药物基因自动临床决策支持。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-09-11 DOI: 10.1080/14622416.2024.2394014
Amanda Massmann, Joel Van Heukelom, Max Weaver, April Schultz, Debbie M Figueroa, Adam Stys, Tomasz P Stys, Kurt D Christensen
{"title":"Evaluation of pharmacogenetic automated clinical decision support for clopidogrel.","authors":"Amanda Massmann, Joel Van Heukelom, Max Weaver, April Schultz, Debbie M Figueroa, Adam Stys, Tomasz P Stys, Kurt D Christensen","doi":"10.1080/14622416.2024.2394014","DOIUrl":"10.1080/14622416.2024.2394014","url":null,"abstract":"<p><p><b>Aim:</b> Clopidogrel requires <i>CYP2C19</i> activation to have antiplatelet effects. Pharmacogenetic testing to identify patients with impaired <i>CYP2C19</i> function can be coupled with clinical decision support (CDS) alerts to guide antiplatelet prescribing. We evaluated the impact of alerts on clopidogrel prescribing.<b>Materials & methods:</b> We retrospectively analyzed data for 866 patients in which <i>CYP2C19</i>-clopidogrel CDS was deployed at a single healthcare system during 2015-2023.<b>Results:</b> Analyses included 2,288 alerts. CDS acceptance rates increased from 24% in 2015 to 63% in 2023 (<i>p</i> < 0.05). Adjusted analyses also showed higher acceptance rates when clopidogrel had been ordered for a percutaneous intervention (OR: 28.7, <i>p</i> < 0.001) and when cardiologists responded to alerts (OR: 2.11, <i>p</i> = 0.001).<b>Conclusion:</b> CDS for <i>CYP2C19</i>-clopidogrel was effective in reducing potential drug-gene interactions. Its influence varied by clinician specialty and medication indications.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142293125","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice. PriME-PGx 计划的最新进展：药物遗传学在日常临床实践中的发展。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-08-08 DOI: 10.1080/14622416.2024.2375188
Eva González-Iglesias, Francisco Abad-Santos
{"title":"Update on the PriME-PGx initiative: evolution of pharmacogenetics in daily clinical practice.","authors":"Eva González-Iglesias, Francisco Abad-Santos","doi":"10.1080/14622416.2024.2375188","DOIUrl":"10.1080/14622416.2024.2375188","url":null,"abstract":"<p><p>In 2021, the Clinical Pharmacology Department of Hospital Universitario de La Princesa launched the PriME-PGx initiative (Multidisciplinary Initiative of the Hospital Universitario de La Princesa for the Implementation of Pharmacogenetics) to promote the expansion of pharmacogenetics in hospitalized patients. We establish seven pharmacogenetic profiles based on the specific needs of seven departments: Oncology, Pain Unit, Neuropsychiatry, Internal or Infectious Medicine, Cardiology, Gastroenterology and Immunosuppressants. The experience of the last 3 years reflects a total of 1421 reports (37.4% being oncology profiles), with a gradual increase in the number of requests each year. With this project, we aim to expand the availability and utility of pharmacogenetic biomarkers to achieve personalised therapy that avoids adverse drug reactions and therapeutic failure.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141902601","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Antiplatelet therapy guided by CYP2C19 point-of-care pharmacogenetics plus multidimensional treatment decisions. 以 CYP2C19 床旁药物遗传学为指导的抗血小板疗法加上多维治疗决策。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-01-17 DOI: 10.2217/pgs-2023-0200
Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann
{"title":"Antiplatelet therapy guided by <i>CYP2C19</i> point-of-care pharmacogenetics plus multidimensional treatment decisions.","authors":"Victor Voicu, Nicolas Diehm, Igal Moarof, Sarah Parejo, Florent Badiqué, Andrea Burden, David Niedrig, Markus Béchir, Stefan Russmann","doi":"10.2217/pgs-2023-0200","DOIUrl":"10.2217/pgs-2023-0200","url":null,"abstract":"<p><p><b>Aim:</b> Implementation of <i>CYP2C19</i> point-of-care (POC) pharmacogenetic (PGx) testing with personalized treatment recommendations. <b>Methods:</b> POC <i>CYP2C19</i> genotyping plus expert evaluation of risk factors for ischemic and bleeding events. <b>Results:</b> 167 patients underwent PGx testing, 54 (32.3%) were <i>CYP2C19</i> loss of function carriers, and POC versus standard PGx analysis results for <i>*2</i> and <i>*3</i> variants matched in 100%. Antiplatelet therapy was adjusted in 44 patients (26.3%), but always required consideration of patient-specific factors. <b>Conclusion:</b> <i>CYP2C19</i> POC-PGx is reliable and offers clinically relevant advantages for immediate evidence-based adaptations of antiplatelet therapy, whereas in less acute cases conventional PGx testing can also have advantages. Antiplatelet therapy has become more complex, and implementation of PGx-based personalized antiplatelet therapy requires complementary expert knowledge.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139478783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychiatric Level 1A evidence pharmacogenomics in a Brazilian admixed cohort and global populations. 巴西混血队列和全球人群的精神病 1A 级证据药物基因组学。
IF 2.1 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-01-30 DOI: 10.2217/pgs-2023-0211
Helena Pereira Ribeiro, Beatriz Meza Baraldi, Fernanda Rodrigues-Soares, Aline Cristiane Planello
{"title":"Psychiatric Level 1A evidence pharmacogenomics in a Brazilian admixed cohort and global populations.","authors":"Helena Pereira Ribeiro, Beatriz Meza Baraldi, Fernanda Rodrigues-Soares, Aline Cristiane Planello","doi":"10.2217/pgs-2023-0211","DOIUrl":"10.2217/pgs-2023-0211","url":null,"abstract":"<p><p><b>Purpose:</b> To compare minor allele frequencies (MAFs) of psychiatric drug response variants in a Brazilian admixed cohort with global populations and other Brazilian groups. <b>Methods:</b> PharmGKB MAFs were gathered from publicly available genetic datasets for Brazil and worldwide. <b>Results:</b> Among 146 variants in <i>CYP2D6</i> and <i>CYP2C19</i>, 41 were present in Brazil, mostly rare (MAF <1%). 11 variants showed significant MAF differences with large effect sizes compared with global populations. <i>CYP2C19*3</i> (rs4986893), <i>CYP2C19*17</i> (rs12248560), <i>CYP2D6*17</i> (rs28371706-A) and <i>CYP2D6*29</i> (rs61736512) exhibited higher frequencies in Brazil, with the latter three also differing from other Brazilian groups. <b>Conclusion:</b> This study highlights significant pharmacogenomic diversity in Brazil and globally, underscoring the need for more research in personalized psychiatric drug therapy.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":2.1,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139574585","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention. 接受经皮冠状动脉介入治疗的 CYP2C19 中间代谢者的基因型指导处方预测因子。
IF 1.9 4区 医学
Pharmacogenomics Pub Date : 2024-01-01 Epub Date: 2024-06-06 DOI: 10.1080/14622416.2024.2355862
Joshua J Park, Gervacio Y Cabel, Kevin K Cheng, Jefferson Dang, Amer K Ardati, Jin Han, James C Lee
{"title":"Genotype-guided prescribing predictors in CYP2C19 intermediate metabolizers receiving percutaneous coronary intervention.","authors":"Joshua J Park, Gervacio Y Cabel, Kevin K Cheng, Jefferson Dang, Amer K Ardati, Jin Han, James C Lee","doi":"10.1080/14622416.2024.2355862","DOIUrl":"10.1080/14622416.2024.2355862","url":null,"abstract":"<p><p><b>Background:</b> Previous differences in guideline recommendation strength for CYP2C19 intermediate metabolizers may have limited genotype (PGx)-optimal post-percutaneous coronary intervention antiplatelet prescribing.<b>Results:</b> In this single-center retrospective observational cohort study of CYP2C19 intermediate metabolizers, patients prescribed PGx-optimal therapy were younger and less likely on anticoagulation (2 vs 12%; <i>p</i> = 0.006). More patients prescribed PGx-optimal therapy possessed commercial insurance (36 vs 7%; <i>p</i> < 0.001), which was a predictor for PGx-optimal selection (OR: 6.464; 95% CI: 2.386-17.516; <i>p</i> < 0.001).<b>Conclusion:</b> Anticoagulation use was significantly associated with clopidogrel use (OR: 0.138; 95% CI: 0.026<b>-</b>0.730; <i>p</i> = 0.020). No statistical difference in composite major adverse cardiovascular events (5 vs 14%; <i>p</i> = 0.173) or bleeding (8 vs 6%; Not significant) was observed between PGx-optimal and PGx-suboptimal therapy.</p>","PeriodicalId":20018,"journal":{"name":"Pharmacogenomics","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11404693/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141331621","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信